Stock Research for BMRN

BMRN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BMRN Stock Chart & Research Data

The BMRN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BMRN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BMRN Due diligence Resources & Stock Charts

The BMRN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BMRN Detailed Price Forecast - CNN Money CNN View BMRN Detailed Summary - Google Finance
Yahoo View BMRN Detailed Summary - Yahoo! Finance Zacks View BMRN Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View BMRN Trends & Analysis - Trade-Ideas Barrons View BMRN Major Holders - Barrons
NASDAQ View BMRN Call Transcripts - NASDAQ Seeking View BMRN Breaking News & Analysis - Seeking Alpha
Spotlight View BMRN Annual Report - CompanySpotlight.com OTC Report View BMRN OTC Short Report - OTCShortReport.com
TradeKing View BMRN Fundamentals - TradeKing Charts View BMRN SEC Filings - Bar Chart
WSJ View Historical Prices for BMRN - The WSJ Morningstar View Performance/Total Return for BMRN - Morningstar
MarketWatch View the Analyst Estimates for BMRN - MarketWatch CNBC View the Earnings History for BMRN - CNBC
StockMarketWatch View the BMRN Earnings - StockMarketWatch MacroAxis View BMRN Buy or Sell Recommendations - MacroAxis
Bullish View the BMRN Bullish Patterns - American Bulls Short Pains View BMRN Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View BMRN Stock Mentions - StockTwits PennyStocks View BMRN Stock Mentions - PennyStockTweets
Twitter View BMRN Stock Mentions - Twitter Invest Hub View BMRN Investment Forum News - Investor Hub
Yahoo View BMRN Stock Mentions - Yahoo! Message Board Seeking Alpha View BMRN Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for BMRN - SECform4.com Insider Cow View Insider Transactions for BMRN - Insider Cow
CNBC View BMRN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BMRN - OTC Markets
Yahoo View Insider Transactions for BMRN - Yahoo! Finance NASDAQ View Institutional Holdings for BMRN - NASDAQ


Stock Charts

FinViz View BMRN Stock Insight & Charts - FinViz.com StockCharts View BMRN Investment Charts - StockCharts.com
BarChart View BMRN Stock Overview & Charts - BarChart Trading View View BMRN User Generated Charts - Trading View


Latest Financial News for BMRN

How Analysts View Tetraphase Pharmaceuticals in April 2018
Posted on Wednesday April 18, 2018

Tetraphase Pharmaceuticals (TTPH) is a clinical-stage biopharmaceutical company focused on creating novel antibiotics. These antibiotics treat serious and life-threatening multidrug-resistant infections by using the company’s proprietary chemistry technology. Its lead product candidate is eravacycline, which is being developed as an intravenous antibiotic.


BioMarin to Host First Quarter 2018 Financial Results Conference Call and Webcast on Wednesday, April 25 at 4:30pm ET
Posted on Wednesday April 18, 2018

SAN RAFAEL, Calif. , April 18, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...


Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018
Posted on Wednesday April 18, 2018

Spark Therapeutics (ONCE) is a leader in the field of gene therapy. Spark Therapeutics’ pipeline of gene therapy product candidates targets the retina, liver, and the central nervous system. Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations, and ten have given it “buy” recommendations.


What Analysts Recommend for CymaBay Therapeutics
Posted on Tuesday April 17, 2018

CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for patients with liver disease and other chronic diseases. Of the eight analysts covering CymaBay Therapeutics in April 2018, two analysts have given the stock a “strong buy” rating, and six analysts have given it a “buy” rating. Of the total 22 analysts covering Pfizer (PFE) in April 2018, two analysts have given the stock a “strong buy” rating, and nine analysts have given it a “buy” rating.


Enter a stock symbol to view the stock details.